Loading organizations...
§ Corporate Venture Capital · Foster City, CA, USA
Venture capital firm investing in genomics and nucleic acid sequencing technologies for human health.
Illumina Ventures is a venture capital firm dedicated to advancing genomics and nucleic acid sequencing technologies to improve human health. It strategically invests in innovative startups, focusing on unlocking the power of the genome. The firm manages a substantial $230 million fund, which expanded from an initial $100 million with an additional $130 million to support its strategic investments. Founding Partner Nick Naclerio and Venture Partner Tom Willis guide the firm's strategy, driving innovation across the life sciences sector. Its diverse portfolio includes companies like Kallyope and Genome Medical, operating in critical areas such as cancer diagnostics, immune assessment, and genomic tools. Established in 2016 by Nicholas Naclerio, Illumina Ventures operates as a venture capital fund backed by corporate, sovereign, institutional, and individual investors.
Key people at Illumina Ventures.
Illumina Ventures has more than 26 tracked investments across 24 companies. The latest tracked deal is $50.0M Other Equity in Alamar Biosciences in January 2026.
Key people at Illumina Ventures.
Illumina Ventures is a venture capital firm dedicated to improving human health by unlocking the power of the genome. Its mission centers on investing in early-stage life science companies, particularly those advancing genomics and precision health. The firm’s investment philosophy emphasizes backing strong teams with broadly applicable technology platforms targeting large markets, supporting companies from seed stage through IPO. Key sectors include life science tools, diagnostics, therapeutics, digital health, and agtech. Illumina Ventures impacts the startup ecosystem by providing not only capital but also deep technical expertise, proprietary deal flow, and strategic partnerships, especially leveraging its unique relationship with Illumina, Inc., a leader in next-generation sequencing (NGS)[1][3][4].
Founded in 2016 as an independent venture fund spun out from Illumina, Inc., Illumina Ventures began with a $100 million anchor investment from Illumina. The founding team comprises investors and entrepreneurs with over 20 years of experience in genomics. Since inception, the firm has expanded its capital base to include other strategic and financial investors such as healthcare and technology corporations, university endowments, sovereign wealth funds, and family offices. This evolution has allowed Illumina Ventures to lead more ambitious projects while maintaining its core focus on genomics and precision health innovation[1][5].
Illumina Ventures rides the wave of rapid advancements in genomics and precision medicine, sectors benefiting from decreasing sequencing costs and increasing biological data availability. The timing is critical as genomics is becoming foundational to healthcare innovation, enabling personalized diagnostics, targeted therapeutics, and novel biotech applications. Market forces such as growing healthcare demands, technological breakthroughs in sequencing, and expanding digital health integration favor Illumina Ventures’ focus. The firm influences the broader ecosystem by building a genomics innovation pipeline, fostering startup growth, and bridging technology development with commercial application[1][3][4].
Looking ahead, Illumina Ventures is poised to deepen its impact by continuing to fund and build transformative genomics startups, leveraging its Labs platform and expanding its strategic partnerships. Trends shaping its journey include the integration of AI with genomics, expansion of precision health into new therapeutic areas, and the rise of synthetic biology and agtech applications. As genomics becomes increasingly central to healthcare and biotechnology, Illumina Ventures’ role as a catalyst and ecosystem builder is likely to grow, further accelerating innovation that improves human health[2][3][4]. This aligns tightly with its founding vision to unlock the power of the genome for better health outcomes.